Filana Therapeutics (FLNA) Other Non-Current Liabilities (2010 - 2026)
Filana Therapeutics (FLNA) posted quarterly Other Non-Current Liabilities of $136000.0 for Q2 2026, up 72.15% year-over-year from $79000.0 in Q2 2025, and up 22.52% quarter-over-quarter from $111000.0 in Q1 2026.
Filana Therapeutics (FLNA) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Filana Therapeutics' Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $136000.0 for Q2 2026.
- In Q2 2026, Other Non-Current Liabilities rose 72.15% year-over-year to $136000.0; the TTM figure through Jun 2026 stood at $136000.0 (up 72.15% YoY), while the FY2025 annual figure was $118000.0, up 49.37% from the prior year.
- Other Non-Current Liabilities for Q2 2026 stood at $136000.0, up from $111000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $201000.0 in Q2 2022, with the low at $79000.0 in Q4 2024.
- The 5-year median for Other Non-Current Liabilities is $119000.0 (2025), against an average of $137461.5.
- The sharpest annual moves came in 2022 and 2026: Other Non-Current Liabilities rose 1.55% in 2022, then surged 72.15% in 2026.
- Filana Therapeutics' Other Non-Current Liabilities stood at $197000.0 in 2022, then changed by 0.0% to $197000.0 in 2023, then plunged by 59.9% to $79000.0 in 2024, then surged by 49.37% to $118000.0 in 2025, then climbed by 15.25% to $136000.0 in 2026.
- Business Quant data shows FLNA's Other Non-Current Liabilities at $136000.0 in Q2 2026, $111000.0 in Q1 2026, and $118000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Filana Therapeutics | 45.29 Mn | 45.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 136,000.00 |
| Mar 31, 2026 | 111,000.00 |
| Dec 31, 2025 | 118,000.00 |
| Sep 30, 2025 | 119,000.00 |
| Jun 30, 2025 | 79,000.00 |
| Mar 31, 2025 | 79,000.00 |
| Dec 31, 2024 | 79,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Mar 31, 2023 | 197,000.00 |
| Dec 31, 2022 | 197,000.00 |
| Sep 30, 2022 | 197,000.00 |
| Jun 30, 2022 | 201,000.00 |
| Mar 31, 2022 | 194,000.00 |
| Dec 31, 2021 | 194,000.00 |
| Sep 30, 2021 | 194,000.00 |
| Sep 30, 2011 | 434,000.00 |
| Jun 30, 2011 | 432,000.00 |
| Dec 31, 2010 | 431,000.00 |